Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Merck & Co's efforts to diversify its cancer ... a wide-ranging alliance with China's Kelun-Biotech that spans seven antibody-drug conjugates (ADCs) in early development. Merck is paying a ...

when Merck entered into an agreement with Daiichi Sankyo (OTCPK:DSKYF) to develop several antibody-drug conjugates. For comparison, and using Seeking Alpha data, Merck's non-GAAP EPS is expected ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

The antibody in this ATC targets CD47 ... PF-24-1156745-01-ET), the Radiological Society of North America (RR1644), the SITC-Merck Cancer Immunotherapy Clinical Fellowship, and the American ...

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...